Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma:Results From the Dutch Expanded Access Program
Toxicity of immune checkpoint inhibitors such as ipilimumab and nivolumab is likely associated with clinical efficacy. In this study, we aim to evaluate this association for pembrolizumab. To this end, data of 147 patients included in the Dutch cohort of the Pembrolizumab Expanded Access Program were collected. All data were collected prospectively. Patients with adverse events (AEs) at any time during therapy showed a higher chance of achieving disease control compared with patients without AEs (low-grade AEs vs. no AEs: odds ratio=12.8, P=0.0002, high-grade AEs vs. no AEs: odds ratio=38.5, P... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2019 |
Reihe/Periodikum: | Bisschop , C , Wind , T T , Blank , C U , Koornstra , R H T , Kapiteijn , E , Van den Eertwegh , A J M , De Groot , J W B , Jalving , M & Hospers , G A P 2019 , ' Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma : Results From the Dutch Expanded Access Program ' , Journal of Immunotherapy , vol. 42 , no. 6 , pp. 208-214 . https://doi.org/10.1097/CJI.0000000000000271 |
Schlagwörter: | melanoma / pembrolizumab / adverse events / disease control / progression-free survival / overall survival / IMMUNE / NIVOLUMAB / EFFICACY / IPILIMUMAB / ANTI-PD-1 / SAFETY |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-29029099 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/e6ccdf93-0d9a-4c16-bd4e-d4f276edeba2 |